רווח למניה בשנים עשר החודשים האחרונים: Personalis Inc (PSNL)

Genomic sequencing costs and the implementation of MRD tests are creating financial pressure, as evidenced by the 12-month earnings per share history, where the current level sits around -1.15. Personalis, Inc. (PSNL) can achieve optimization through its NeXt Personal AI platform for early screening and its status as a recognized scientific leader in high-sensitivity analysis, which strengthens the trust of major medical centers.

Personalis, Inc. (PSNL) monetization of genetic data arrays through contracts with pharma giants directly impacts the business's bottom-line profitability, reflecting the efficiency of converting intellectual capital into actual revenue. This metric is calculated as the ratio of net income to the number of shares, and analyzing the rolling annual net income per share on GURU.Markets allows for the timely identification of trend degradation to ensure prompt portfolio rebalancing.